{"id":417,"date":"2023-10-25T13:19:00","date_gmt":"2023-10-25T13:19:00","guid":{"rendered":"https:\/\/beta.oxforddrugdesign.com\/?page_id=417"},"modified":"2023-11-17T17:43:45","modified_gmt":"2023-11-17T17:43:45","slug":"news","status":"publish","type":"page","link":"https:\/\/oxforddrugdesign.com\/index.php\/news\/","title":{"rendered":"News"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJanuary 12, 2026<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design announces further in vivo validation of novel oncology therapeutic mechanism<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced an important milestone in the development of a potential first-in-class cancer […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 23, 2025<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tIN MEMORIAM: Graham Richards CBE FRS 1939-2025 Founding Chairman, Oxford Drug Design Ltd<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

With thanks to Dr. Sujuan Ba, President & CEO of the National Foundation or Cancer Research (NFCR) who had provided funding for […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tFebruary 20, 2025<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design awarded \u00a31m PACE funding to progress uUTI treatment<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

As part of company\u2019s tRNA synthetase development in oncology and infections  Oxford Drug Design has been awarded \u00a31m in funding to progress […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJanuary 15, 2025<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design achieves further in vivo validation of novel approach against multiple tumours<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced today additional in vivo validation for its first-in-class approach against cancer […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tSeptember 26, 2024<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design awarded share of \u00a33m Cystic Fibrosis Collaborative Drug Discovery Programme<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

The cross-sector initiative provides funding and support to accelerate new treatments for lung infections in Cystic Fibrosis  September 26th 2024, United Kingdom: […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tAugust 2, 2024<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design announces initial in vivo validation of novel oncology therapeutic mechanism<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Appoints oncologist Prof. Sarah Blagden to its Scientific Advisory Board. Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 22, 2024<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy. The CRUK (Cancer Research UK) Scotland Institute […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMarch 22, 2023<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Targeted protein degradation discovery programme to harness artificial intelligence to identify new E3 Ligase-based therapeutic strategies. Oxford Drug Design, a biotechnology company […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tSeptember 20, 2022<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design appoints Dr Richard Cooper as Head of Machine Learning and Prof. Xiang-Lei Yang to its Scientific Advisory Board<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering AI platform to develop novel molecules for use in cancer […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tSeptember 5, 2022<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tDr Aras Asaad presents at the 5th Artificial Intelligence in Chemistry Symposium<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr Aras Asaad presented his work in exploiting existing 2D image-based deep learning architectures to capture 3D molecular information at this year’s […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tAugust 31, 2022<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tProf. W. Graham Richards on the origins of the Journal of the Molecular Graphics and Modelling Society<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design’s Founder and current Chairman, Prof. W. Graham Richards CBE FRS has recently written an account of the origins of […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJune 10, 2022<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attending the 28th tRNA Conference 2022<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Paul Finn, CSO, will be attending the 28th tRNA Conference, 12-16 June 2022 in Columbus, Ohio, USA.  On 13 June at 4:45pm […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 19, 2022<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design receives $2.7 (\u00a32.2) million in bridge round commitments<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised $2.7M (\u00a32.2M) in funding […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 10, 2022<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design to Present at ASM Microbe 2022<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Paul Finn, CSO, will be attending ASM Microbe 2022, 9-13 June in Washington D.C. USA and making an Oral Presentation on Saturday […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tNovember 1, 2021<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tDr. Grace Edmund presents at ICARe<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr. Grace Edmund was selected to attend the Interdisciplinary Course on Antibiotics and Resistance (ICARe) hosted by Les Pensi\u00e8res Center for Global […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tOctober 8, 2021<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends the CARTNET Symposium<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Marco Albanese recently presented his work in designing novel histidine kinases inhibitors at the CARTNET Symposium in Valencia. He described using Oxford […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tNovember 17, 2020<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design welcome new CEO Dr. Alan D. Roth<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design Board of Directors announces the appointment of Dr. Alan D. Roth Chief Executive Officer, effective immediately. Alan takes over […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tOctober 26, 2020<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design at virtual conferences<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design recently attended both the virtual 3rd RSC-BMCS \/ RSC-CICAG Artificial Intelligence in Chemistry and UK-QSAR Autumn 2020 meetings. Dr […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tOctober 16, 2020<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tProf. Graham Richards speaks to Biospring<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Prof. Graham Richards recently spoke to Dr. Michelle Dipp, Co-Founder and Managing Partner of Biospring, on the topic of computer-aided molecular design.<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJune 8, 2020<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design shortlisted for CogX 2020 award for \u2018Best AI Product in Health\u2019<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design is proud to have been shortlisted for this year\u2019s CogX award for \u2018Best AI product in health\u2019. CogX is […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tFebruary 19, 2020<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tMeet ODD at these spring events<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Unfortunately due to COVID-19 the events listed have been cancelled. We look forward to meeting you at future events. Oxford Drug Design […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tNovember 5, 2019<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design wins UK-China AMR grant and boosts funding with investment from the Angel CoFund<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford University biotech spin-out receives over \u00a32 million to take its drug discovery programme to the next level. Oxford Drug Design Limited […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tOctober 14, 2019<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design presents at CDD 2019 Autumn Seminar Series<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design recently attended an event at the Said Buisness School, in Oxford showcasing the latest developments of Collaborative Drug Discovery’s […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJune 18, 2019<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design receives over \u00a38m in grant and equity investment<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design announced today success in securing funds, totalling over \u00a38m, from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the UK […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 28, 2019<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tDr Michael Charlton presents at CCG’s European User Group Meeting<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr Michael Charlton recently presented our work in designing novel aminoacyl tRNA synthetase inhibitors at the Chemical Computing Group’s European User Group […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMarch 27, 2019<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends Fragments 2019<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Marco Albanese recently presented a poster on using fragment-based approaches to discover compounds targeting the ATP-binding domain of bacterial histidine kinases at […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tNovember 14, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends the 2nd SCI\/RSC Symposium on Antimicrobial Drug Discovery<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Prof. Paul Finn presented on a major cause of failure of antibacterial drug discovery projects, failure to accumulate sufficiently at the site […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJuly 6, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends the Theory and Modelling in Chemical Sciences Annual Symposium<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr Paul Finn attended the theory and modelling chemical sciences annual symposium in Bristol. The\u00a0theory and modelling in chemical sciences\u00a0centre for doctoral […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 24, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends the JPI-AMR workshop in Oxford<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design attended the JPI-AMR workshop on \u201cGetting small drug-like molecules into Gram-negative bacteria\u201d. This workshop provided an excellent opportunity to […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 18, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends CCG\u2019s European User Group Meeting and Conference<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr. Jerome Wicker recently presented our latest work on the effect of charge and conformation on enrichment of DUD-E targets. Using both […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 11, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tDr. Pamela Brown FRSC joins the Oxford Drug Design Scientific Advisory Board<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design is pleased to announce the appointment of Dr. Pamela Brown FRSC to the company\u2019s Scientific Advisory Board. Dr. Brown […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 9, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tProf. Graham Richards has been elected a Fellow of the Royal Society<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design Chairman and Co-founder Prof. W. Graham Richards has been elected a Fellow of the Royal Society. Fellowship is awarded […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 2, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tProf. Graham Richards awarded the Richard J. Bolte Sr. Award for Supporting Industries<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design Chairman and Co-founder Prof. W. Graham Richards has been awarded the Richard J. Bolte Sr. Award for Supporting Industries. […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tApril 12, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends the Joint UK-QSAR\/MGMS meeting<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design attended the joint UK-QSAR\/Molecular Graphics and Modelling Society (MGMS) conference on the theme of \u201cStructure Activity Relationships\u201d. Dr Grace […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMarch 8, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design in Chemistry World<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design has contributed to an article in the March edition of Chemistry World. The article, entitled “Countdown to the last […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJanuary 18, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tN-Leucinyl Benzenesulfonamides as LeuRS Inhibitors<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

ODD scientists and collaborators have published a research paper describing the discovery of a new class of aminoacyl-tRNA synthetase inhibitors, N-Leucinyl benzenesulfonamides. […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJanuary 16, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design attends Medicines Discovery Catapult\u2019s Antimicrobial Resistance Workshop<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr. Michael Charlton presented a review of literature analyses of the physical properties of antibacterial compounds. This included an emphasis on our […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJanuary 1, 2018<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tCARTNET Begins – Oxford Drug Design starts work on AMR training network<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design has started work on a new \u20ac3.4 Million Horizon 2020 Marie Curie European Training Network –\u00a0CARTNET, \u201cCombating Antimicrobial Resistance […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tNovember 6, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design present on novel LeuRS inhibitors at aaRS2017<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Dr. Michael Charlton and Dr. Grace Edmund recently reported our work in the design of novel compounds to target the synthetic active […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tOctober 10, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design win EU support for antibacterial research<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

The European Commission has awarded 3.4 Million Euro under the Horizon 2020 programme to a new Marie Curie European Training Network –\u00a0CARTNET, […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJuly 18, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tProf. David Livermore joins the Oxford Drug Design Scientific Advisory Board<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design is pleased to announce the addition of Prof. David Livermore to our Scientific Advisory Board. David Livermore gained his […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tJune 29, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tJames B. Kahn, M.D. FIDSA, joins the Oxford Drug Design Scientific Advisory Board<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design is pleased to announce the appointment of James B. Kahn, M.D. FIDSA, to the company\u2019s Scientific Advisory Board. Dr. […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMay 10, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tInhibOx relauches as Oxford Drug Design<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

InhibOx has relaunched as Oxford Drug Design to reflect its transition to a biotechnology company focused on internal drug discovery. Our lead […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tApril 1, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design secures $1.9m financing<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design has raised nearly $2m (\u00a31.5m) of private investment to enable it to progress a novel antibacterial programme and continue […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div>
\n\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\tMarch 1, 2017<\/span><\/a><\/span>\t\t\t\t\t|<\/span> By Admin<\/a> <\/span>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t

\n\tOxford Drug Design starts work on $1.1m project to fight drug-resistant bacteria<\/a>\n<\/h3>\t\t\t
\n\t\t\t\t
\n\t

Oxford Drug Design (formerly InhibOx) has started work on a $1.1m (\u00a3900k) grant funded project to develop novel antibiotics. The project started […]<\/p>\n<\/div>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

<\/div><\/a>\n\t\t\t<\/div>\n<\/article><\/div><\/div><\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

March 22, 2023 | By Admin Oxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery Targeted protein degradation discovery […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-417","page","type-page","status-publish","hentry"],"yoast_head":"\nNews - Oxford Drug Design<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxforddrugdesign.com\/index.php\/news\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News - Oxford Drug Design\" \/>\n<meta property=\"og:description\" content=\"March 22, 2023 | By Admin Oxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery Targeted protein degradation discovery […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxforddrugdesign.com\/index.php\/news\/\" \/>\n<meta property=\"og:site_name\" content=\"Oxford Drug Design\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-17T17:43:45+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@OxDrugDes\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/oxforddrugdesign.com\/index.php\/news\/\",\"url\":\"https:\/\/oxforddrugdesign.com\/index.php\/news\/\",\"name\":\"News - Oxford Drug Design\",\"isPartOf\":{\"@id\":\"https:\/\/oxforddrugdesign.com\/#website\"},\"datePublished\":\"2023-10-25T13:19:00+00:00\",\"dateModified\":\"2023-11-17T17:43:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/oxforddrugdesign.com\/index.php\/news\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/oxforddrugdesign.com\/index.php\/news\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/oxforddrugdesign.com\/index.php\/news\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/oxforddrugdesign.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/oxforddrugdesign.com\/#website\",\"url\":\"https:\/\/oxforddrugdesign.com\/\",\"name\":\"Oxford Drug Design\",\"description\":\"A new leader in AI-based drug discovery\",\"publisher\":{\"@id\":\"https:\/\/oxforddrugdesign.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/oxforddrugdesign.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/oxforddrugdesign.com\/#organization\",\"name\":\"Oxford Drug Design\",\"url\":\"https:\/\/oxforddrugdesign.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/oxforddrugdesign.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/oxforddrugdesign.com\/wp-content\/uploads\/2023\/10\/odd-logo-tall.jpeg\",\"contentUrl\":\"https:\/\/oxforddrugdesign.com\/wp-content\/uploads\/2023\/10\/odd-logo-tall.jpeg\",\"width\":200,\"height\":200,\"caption\":\"Oxford Drug Design\"},\"image\":{\"@id\":\"https:\/\/oxforddrugdesign.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/OxDrugDes\",\"https:\/\/www.linkedin.com\/company\/oxforddrugdesign?originalSubdomain=uk\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"News - Oxford Drug Design","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxforddrugdesign.com\/index.php\/news\/","og_locale":"en_US","og_type":"article","og_title":"News - Oxford Drug Design","og_description":"March 22, 2023 | By Admin Oxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery Targeted protein degradation discovery […]","og_url":"https:\/\/oxforddrugdesign.com\/index.php\/news\/","og_site_name":"Oxford Drug Design","article_modified_time":"2023-11-17T17:43:45+00:00","twitter_card":"summary_large_image","twitter_site":"@OxDrugDes","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/oxforddrugdesign.com\/index.php\/news\/","url":"https:\/\/oxforddrugdesign.com\/index.php\/news\/","name":"News - Oxford Drug Design","isPartOf":{"@id":"https:\/\/oxforddrugdesign.com\/#website"},"datePublished":"2023-10-25T13:19:00+00:00","dateModified":"2023-11-17T17:43:45+00:00","breadcrumb":{"@id":"https:\/\/oxforddrugdesign.com\/index.php\/news\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxforddrugdesign.com\/index.php\/news\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/oxforddrugdesign.com\/index.php\/news\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxforddrugdesign.com\/"},{"@type":"ListItem","position":2,"name":"News"}]},{"@type":"WebSite","@id":"https:\/\/oxforddrugdesign.com\/#website","url":"https:\/\/oxforddrugdesign.com\/","name":"Oxford Drug Design","description":"A new leader in AI-based drug discovery","publisher":{"@id":"https:\/\/oxforddrugdesign.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxforddrugdesign.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/oxforddrugdesign.com\/#organization","name":"Oxford Drug Design","url":"https:\/\/oxforddrugdesign.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxforddrugdesign.com\/#\/schema\/logo\/image\/","url":"https:\/\/oxforddrugdesign.com\/wp-content\/uploads\/2023\/10\/odd-logo-tall.jpeg","contentUrl":"https:\/\/oxforddrugdesign.com\/wp-content\/uploads\/2023\/10\/odd-logo-tall.jpeg","width":200,"height":200,"caption":"Oxford Drug Design"},"image":{"@id":"https:\/\/oxforddrugdesign.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/OxDrugDes","https:\/\/www.linkedin.com\/company\/oxforddrugdesign?originalSubdomain=uk"]}]}},"_links":{"self":[{"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/pages\/417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/comments?post=417"}],"version-history":[{"count":43,"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/pages\/417\/revisions"}],"predecessor-version":[{"id":2324,"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/pages\/417\/revisions\/2324"}],"wp:attachment":[{"href":"https:\/\/oxforddrugdesign.com\/index.php\/wp-json\/wp\/v2\/media?parent=417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}